Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin

Periostin (Postn) is a matricellular protein preferentially expressed by osteocytes and periosteal osteoblasts in response to mechanical stimulation and parathyroid hormone (PTH). Whether and how periostin expression influences bone anabolism, however, remains unknown. We investigated the skeletal response of adult Postn−/− and Postn+/+ mice to intermittent PTH. Compared with Postn+/+, Postn−/− mice had a lower bone mass, cortical bone volume, and strength response to PTH. PTH-stimulated bone-forming indices were all significantly lower in Postn−/− mice, particularly at the periosteum. Furthermore, in vivo stimulation of Wnt-β-catenin signaling by PTH, as evaluated in TOPGAL reporter mice, was inhibited in the absence of periostin (TOPGAL;Postn−/− mice). PTH stimulated periostin and inhibited MEF2C and sclerostin (Sost) expression in bone and osteoblasts in vitro. Recombinant periostin also suppressed Sost expression, which was mediated through the integrin αVβ3 receptor, whereas periostin-blocking antibody prevented inhibition of MEF2C and Sost by PTH. In turn, administration of a Sost-blocking antiboby partially restored the PTH-mediated increase in bone mass in Postn−/− mice. In addition, primary osteoblasts from Postn−/− mice showed a lower proliferation, mineralization, and migration, both spontaneously and in response to PTH. Osteoblastic gene expression levels confirmed a defect of Postn−/− osteoblast differentiation with and without PTH, as well as an increased osteoblast apoptosis in the absence of periostin. These data elucidate the complex role of periostin on bone anabolism, through the regulation of Sost, Wnt-β-catenin signaling, and osteoblast differentiation.

[1]  R. Midura,et al.  Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. , 2009, Bone.

[2]  T. Martin,et al.  Osteoclast-derived activity in the coupling of bone formation to resorption. , 2005, Trends in molecular medicine.

[3]  S. Ferrari,et al.  Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. , 2009, Bone.

[4]  Jian Q. Feng,et al.  periostin Null Mice Exhibit Dwarfism, Incisor Enamel Defects, and an Early-Onset Periodontal Disease-Like Phenotype , 2005, Molecular and Cellular Biology.

[5]  R. Rizzoli,et al.  β‐Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  G. Loots,et al.  Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  S. Reppe,et al.  Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. , 2010, Matrix biology : journal of the International Society for Matrix Biology.

[8]  A. Robling,et al.  Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. , 2011, Endocrinology.

[9]  S. Bao,et al.  The multifaceted role of periostin in tumorigenesis , 2009, Cellular and Molecular Life Sciences.

[10]  P. Roberson,et al.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.

[11]  M. Bouxsein,et al.  Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. , 2005, Endocrinology.

[12]  O. Leupin,et al.  Does osteocytic SOST suppression mediate PTH bone anabolism? , 2010, Trends in Endocrinology & Metabolism.

[13]  D. Goltzman,et al.  Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. , 2007, Endocrinology.

[14]  D. Goltzman,et al.  Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized Mice , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  S. Reppe,et al.  Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. , 2006, Bone.

[16]  P. Roberson,et al.  Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. , 2010, Endocrinology.

[17]  D. Bednarik,et al.  Expression and function of periostin‐isoforms in bone , 2004, Journal of cellular biochemistry.

[18]  P. Kostenuik,et al.  Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone? , 2010, The Journal of Biological Chemistry.

[19]  J. Bilezikian,et al.  Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. , 2008, Endocrinology.

[20]  J. Bilezikian,et al.  The cell biology of parathyroid hormone in osteoblasts , 2008, Current osteoporosis reports.

[21]  Xiaoli Shen,et al.  PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile , 2003, Molecular and Cellular Endocrinology.

[22]  Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk , 2012, Osteoporosis International.

[23]  R. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. , 2007, Bone.

[24]  R. Baron,et al.  Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Bouxsein,et al.  β‐Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  R. Lindsay,et al.  A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short‐Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  L. Gelbert,et al.  Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray , 2005, Journal of cellular biochemistry.

[28]  K. Lau,et al.  Up-regulation of the Wnt, Estrogen Receptor, Insulin-like Growth Factor-I, and Bone Morphogenetic Protein Pathways in C57BL/6J Osteoblasts as Opposed to C3H/HeJ Osteoblasts in Part Contributes to the Differential Anabolic Response to Fluid Shear* , 2006, Journal of Biological Chemistry.

[29]  D. Notterman,et al.  Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis* , 2007, Journal of Biological Chemistry.

[30]  R. Nissenson,et al.  PTH Differentially Regulates Expression of RANKL and OPG , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  Mark L. Johnson,et al.  Wnt/β-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone* , 2006, Journal of Biological Chemistry.

[32]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[33]  D. Fishman,et al.  Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. , 2002, Cancer research.

[34]  M. Kraenzlin,et al.  Parathyroid hormone analogues in the treatment of osteoporosis , 2011, Nature Reviews Endocrinology.

[35]  F. Kuhlencordt,et al.  [Primary hyperparathyroidism]. , 1979, Deutsche medizinische Wochenschrift.

[36]  Xi He,et al.  LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way , 2004, Development.

[37]  M. Foti,et al.  The Matricellular Protein Periostin Is Required for Sost Inhibition and the Anabolic Response to Mechanical Loading and Physical Activity* , 2009, The Journal of Biological Chemistry.

[38]  F. Natt,et al.  Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  M. Fukayama,et al.  Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. , 2009, Human pathology.

[40]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[41]  L. Lanyon,et al.  Wnt/β-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor α* , 2007, Journal of Biological Chemistry.